<DOC>
	<DOCNO>NCT00440362</DOCNO>
	<brief_summary>AVX502 , alphavirus replicon vaccine express influenza HA protein , candidate vaccine influenza . The objective Phase 1 study test safety vaccine immune response vaccine healthy volunteer 18-40 year age . Volunteers assign randomization receive either vaccine inactive substance ( placebo ) injection arm one two occasion 2 month . The study last 4 month total 8 visit .</brief_summary>
	<brief_title>A Phase 1/2 Clinical Trial Alphavirus Replicon Vaccine Influenza</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled Phase 1/2 study safety immunogenicity AVX502 vaccine two dosage level two route administration healthy volunteer conduct single research center . A total 216 participant enrol . Participants randomize receive active vaccine one two dosage level placebo 4:4:1 ratio . Within active dosage level placebo subgroup , participant randomize receive injection either IM SC injection 1:1 ratio , also randomize receive either 1 injection ( Week 0 ) 2 injection ( 1 two visit Weeks 0 8 ) 1:1 ratio . Vaccine administer study nurse outpatient set participant follow 4 month first immunization . Safety data include local systemic reactogenicity dose vaccine , collect systematic format use subject memory aid standard grade scale , specific safety laboratory parameter general AEs . Immunogenicity data obtain collect blood define time point immunization separate serum ( measurement antibody HA ELISA hemagglutination inhibition assay vaccine vector VRP neutralization assay ) peripheral blood mononuclear cell ( PMBC ) ( measurement cellular immune response HA peptide ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Between 18 40 year age , inclusive ; 2 . Good general health without significant physical examination finding clinically significant abnormal laboratory result ; 3 . Available participate entire study period approximately 4 month ; 4 . For woman childbearing potential , negative urine pregnancy test screen immunization , agreement consistently use contraception 28 day prior enrollment last protocol visit , sexual activity could lead pregnancy ; 5 . Acceptable laboratory parameter : hemoglobin ≥ 11.2 g/dL woman , ≥ 12.8 g/dL men , white blood cell count 3,300 12,000 cells/mm3 , platelet count 125,000 550,000/mm3 , alanine aminotransferase ( ALT ) within normal range study laboratory , serum creatinine within normal range study laboratory , normal urine dipstick ( negative glucose , negative hemoglobin , negative trace protein ) , negative hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) blood test , negative HIV blood test ; 6 . Willingness blood store 10 year use additional assay evaluate immune response influenza alphavirus vector assay become available 7 . Willingness participate study evidence sign informed consent obtain screen . 1 . Venous access deem inadequate phlebotomy demand study ; 2 . Women breast feeding ; 3 . In female subject , positive urine pregnancy test screen day vaccine injection ; 4 . Receipt influenza vaccine within 12 month prior enrollment ; 5 . Receipt vaccine within 30 day prior enrollment ; 6 . Use investigational agent within 30 day prior enrollment ; 7 . Receipt immunoglobulin blood product within 60 day prior enrollment ; 8 . Use cytotoxic medication within 6 month prior enrollment ; 9 . Use systemic corticosteroid within 6 month prior enrollment ( except participant complete course prednisone , 20 mg per day 7 day , least 1 month prior enrollment eligible enrollment ) ; 10 . Presence factor place individual increase risk severe complication influenza ; 11 . History serious adverse reaction vaccine , include anaphylaxis relate symptom hive , respiratory difficulty , angioedema abdominal pain ; 12 . History autoimmune disease ; 13 . History splenectomy ; 14 . History malignancy within last 3 year ( except participant diagnosis basal cell carcinoma skin eligible enrollment ) ; 15 . Psychiatric condition may interfere ability comply protocol requirement . Specifically excluded person history psychosis within past 3 year history suicidal attempt gesture within past 3 year ; 16 . History medical , occupational family problem result alcohol illicit drug use past 12 month ; 17 . Any condition lead investigator believe participant comply protocol requirement may place participant unacceptable risk participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Flu</keyword>
	<keyword>A/Wyoming/03/2003</keyword>
	<keyword>Alphavirus</keyword>
</DOC>